Silvia Stacchiotti, MD

Medical Oncologist
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardia, Italy

Disclosure information not submitted.

Presentation(s):

• Paper 16 - SACRAL CHORDOMA: A RANDOMIZED AND OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO): INTERIM ANALYSIS

  Thursday, November 14, 2024
  1:45 PM – 3:15 PM PST

• Paper 41 - REFINING THE CONTEMPORARY MANAGEMENT OF PRIMARY RETROPERITONEAL SARCOMA: SETTING NEW STANDARDS WAITING FOR NEW THERAPIES.

  Friday, November 15, 2024
  8:00 AM – 9:00 AM PST

• Paper 79 - PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN LOCALLY ADVANCED OR METASTATIC IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA UNTREATED OR PREVIOUSLY TREATED WITH 1 SYSTEMIC TREATMENT REGIMEN (CHONQUER)

  Saturday, November 16, 2024
  9:00 AM – 10:00 AM PST

• Paper 84 - PLANNED ANALYSIS OF THE PIVOTAL IGNYTE-ESO TRIAL OF LETE-CEL IN PATIENTS WITH SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA.

  Saturday, November 16, 2024
  10:30 AM – 12:00 PM PST

• Paper 100 - REDEFINING RADIOLOGIC RESPONSE IN EPITHELIOID HEMANGIOENDOTHELIOMA: BEYOND RECIST?

  Saturday, November 16, 2024
  2:00 PM – 3:00 PM PST

• Paper 105 - EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES OF VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR: RESULTS FROM THE MOTION PHASE 3 TRIAL

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST

• Paper 106 - SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST

• Paper 107 - PEXIDARTINIB USE IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR: AN ANALYSIS OF THE PHASE III RANDOMIZED ENLIVEN CLINICAL TRIAL ACCORDING TO SURGICAL HISTORY

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST